As always people react to the headline figures and start to read the small print later.
The Company maintains its guidance for the full year ending December 31, 2016, and expects continued revenue growth predominantly from product and service revenue in the US and international markets, driven by the inclusion of the ConfirmMDx test in the NCCN guidelines in the US, additional coverage agreements with major payors, for both ConfirmMDx and SelectMDx, and growing adoption of MDxHealth products among the urology community. The continued infrastructure investments over the last twelve months, particularly in the sales force, managed care, and billing and collections are expected to further improve volume, collections, EBITDA and revenue recognition in the second half.
So, read between the lines:
The sales force cost has now occurred so expect increase sales is expected from it
Billing and collections costs are also in place now so expect money coming in from those past sales.
So from now on sales will continue to increase, revenue recognition will increase and costs will remain stable.
The look for new investors, next year?, will be to increase production in sales in other countries for Confirm and for SelectMDx.
To attract new investors you need to show the future outlook for your company.
This outlook is bright.